Calciumantagonisten bei Höhenkrankheit

  • P. Bärtsch

Zusammenfassung

Die akute Bergkrankheit (ABK) und das Höhenlungenödem (HLÖ) sind Krankheiten, die in den ersten Tagen einer akuten Höhenexposition über 2500–3000 m bei vorher völlig gesunden Personen auftreten können. Der Zusammenhang zwischen diesen höhenbedingten Erkrankungen ist nicht vollständig geklärt. Vereinzelte Fälle von HLÖ ohne vorausgehende ABK sowie Unterschiede bezüglich der Pathophysiologie und Therapie sprechen dafür, daß das HLÖ nicht als Endstadium der ABK angesehen werden kann. Nach einer kurzen Darstellung der Krankheitsbilder soll in diesem Beitrag die Bedeutung der Calciumantagonisten für Prophylaxe und Therapie sowie für das Verständnis der Pathophysiologie dieser Krankheiten dargestellt werden.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Bärtsch P, Shaw S, Franciolli M, Gnädinger MP, Weidmann P (1988) Atrial natriuretic peptide in acute mountain sickness. J Appl Physiol 65: 1929–1937PubMedGoogle Scholar
  2. 2.
    Bärtsch P, Baumgartner R, Waber U, Maggiorini M, Oelz O (1990) Comparison of carbondioxide-enriched, ocygen-enriched, and normal air in the treatment of acute mountain sickness. Lancet 336: 772–775PubMedCrossRefGoogle Scholar
  3. 3.
    Bärtsch P, Maggiorini M, Ritter M, Noti C, Vock P, Oelz O (1991) Prevention of high-altitude pulmonary edema by nifedipine. N Engl J Med 325: 1284–1289PubMedCrossRefGoogle Scholar
  4. 4.
    Bärtsch P, Maggiorini M, Schobersberger W, Shaw S, Rascher W, Girard J, Weidmann P, Oelz O (1991) Enhanced ecercise-induced rise of aldosterone and vasopressin preceding mountain sickness. J Appl Physiol 71: 136–143PubMedGoogle Scholar
  5. 5.
    Bärtsch P (1992) Wer wird bergkrank? Schweiz Med Wschr 122: 307–314PubMedGoogle Scholar
  6. 6.
    Birmingham Medical Research Expeditionary Society Mountain Sickness Study Group (1981) Acetazolamide in control of acute mountain sickness. Lancet I;180–183Google Scholar
  7. 7.
    Bradwell AR, Delamere JP (1982) The effect of acetazolamide on the proteinuria of altitude. Aviat Space Environ Med 53: 40–43PubMedGoogle Scholar
  8. 8.
    Bradwell AR, Imray CHE, Wright A, Delamere J (1993) Acetazolamide or nifedipine in acute mountain sickness prophylaxis? In: Sutton JR (ed) Bradwell AR, Imray CHE, Wright A, Delamere J, p 294 (Abstract)Google Scholar
  9. 9.
    Delabays A, Aebischer N, Vollenweider L, Bartsch P, Scherrer U (1994) Nitric oxide induced reduction of right ventricular volume and pulmonary arterial pressure at high altitude. Circulation 4: 1267 (Abstract)Google Scholar
  10. 10.
    Brigham KL, Woolverton WC, Blake LH, Staub NC (1974) Increased sheep lung vascular permeability caused by pseudomonas bacteria. J Clin Invest 54: 792–804PubMedCrossRefGoogle Scholar
  11. 11.
    Hackett PH, Creagh CE, Grover RF, van Hardenbroek M, Honigman B, Houston CS, Reeves JT, Sophocles AM (1980) High altitude pulmonary edema in persons without the right pulmonary artery. N Engl J Med 302: 1070–1073PubMedCrossRefGoogle Scholar
  12. 12.
    Hackett PH, Roach RC, Hartig GS, Greene ER, Levine BD (1992) The effect of vasodilatators on pulmonary hemodynamics in high altitude pulmonary edema: A comparison. Int J Sports Med 13: S68 - S74PubMedCrossRefGoogle Scholar
  13. 13.
    Hansen JM, Olsen NV, Feldt-Rasmussen B, Kanstrup I-L, Déchaux M, Dubray C, Richalet J-P (1994) Albuminuria and overall capillary permeability of albumin in acute altitude hypoxia. J Appl Physiol 76: 1922–1927PubMedGoogle Scholar
  14. 14.
    Hohenhaus E, Niroomand F, Görre S, Vock P, Oelz O, Bartsch P (1994) Nifedipine does not prevent acute mountain sickness. Am J Respir Crit Care Med 150: 857–860PubMedGoogle Scholar
  15. 15.
    Houston CS, Dickinson J (1975) Cerebral form of high-altitude illness. Lancet I1: 758–761CrossRefGoogle Scholar
  16. 16.
    Houston CS (1960) Acute pulmonary edema of high altitude. N Engl J Med 263: 478–480PubMedCrossRefGoogle Scholar
  17. 17.
    Hultgren HN (1978) High altitude pulmonary edema. In: Staub NC (ed) Lung water and solute exchange. Vol. 7 of Lung biology in health and disease. Marcel Dekker, New York, 437–469Google Scholar
  18. 18.
    Hultgren HN, Lopez CE, Lundberg E, Miller H (1964) Physiologic studies of pulmonary edema at high altitude. Circulation 29: 393–408PubMedGoogle Scholar
  19. 19.
    Jamieson A, Kerr, GW (1992) Treatment of high-altitude pulmonary oedema. Lancet 340: 1468PubMedCrossRefGoogle Scholar
  20. 20.
    Johnson TS, Rock PB (1988) Acute mountain sickness. N Engl J Med 319: 841–845PubMedCrossRefGoogle Scholar
  21. 21.
    Levine BD, Yoshimura K, Kobayashi T, Fukushima M, Shibamoto T, Ueda G (1989) Dexamethasone in the treatment of acute mountain sickness. N Engl J Med 321: 1707–1713PubMedCrossRefGoogle Scholar
  22. 22.
    Maggiorini M, Bühler B, Walter M, Oelz O (1990) Prevalence of acute mountain sickness in the Swiss Alps. Br Med J 301: 853–855CrossRefGoogle Scholar
  23. 23.
    Malo PE, Wasserman MA (1986) The effect of calcium antagonists on histamine and leukotriene-induced tracheal microvascular permeability in the guinea pig. Prostaglandins 32: 221–233PubMedCrossRefGoogle Scholar
  24. 24.
    Matsuzawa Y, Fujimoto K, Kobayashi T, Namushi NR, Harada K, Kohno H, Fukushima M, Kusama S (1989) Blunted hypoxic ventilatory drive in subjects susceptible to high-altitude pulmonary edema. J Appl Physiol 66: 1152–1157PubMedGoogle Scholar
  25. 25.
    Neumann FJ, Ott I, Richardt G, Zimmermann R, Tillmanns H, Kübler W, Rauch B (1992) Effect of gallopamil on neutrophil function: experimental and clinical studies. J Cardiovasc Pharmacol 20: S21 - S25PubMedCrossRefGoogle Scholar
  26. 26.
    Oelz O, Ritter M, Jenni R, Maggiorini M, Waber U, Vock P, Bärtsch P (1989) Nifedipine for high altitude pulmonary edema. Lancet 11: 1241–1244CrossRefGoogle Scholar
  27. 27.
    Oelz O, Notti C, Ritter M, Jenni R, Bärtsch P (1991) Nifedipine for high altitude pulmonary edema. Lancet 337: 556PubMedCrossRefGoogle Scholar
  28. 28.
    Oelz O, Maggiorini M, Ritter M, Noti Ch, Waber U, Vock P, Bärtsch P (1992) Pathophysiologie, Prophylaxe and Therapie des Höhenlungenödems. Schweiz med Wschr 122: 1151–1158PubMedGoogle Scholar
  29. 29.
    Oelz O (1987) A case of high altitude pulmonary edema treated with nifedipine. JAMA 257: 780PubMedCrossRefGoogle Scholar
  30. 30.
    Schoene RB Swenson ER, Pizzo CJ, Hackett PH, Roach RC, Mills WJ, Henderson WR, Martin TR (1988) The lung at high altitude: bronchoalveolar lavage in acute mountain sickness and pulmonary edema. J Appl Physiol 64: 2605–2613PubMedGoogle Scholar
  31. 31.
    Staub NC (1980) Pulmonary edema — hypoxia and overperfusion. N Engl J Med 302: 1085–1087PubMedCrossRefGoogle Scholar
  32. 32.
    West JB, Mathieu-Costello O (1992) Stress failure of pulmonary capillaries: role in lung and heart disease. Lancet 340: 762–767PubMedCrossRefGoogle Scholar
  33. 33.
    Younes M, Bshouty Z, Ali J (1987) Longitudinal distribution of pulmonary vascular resistance with very high pulmonary blood flow. J Appl Physiol 62: 344–358PubMedGoogle Scholar

Copyright information

© Dr. Dietrich Steinkopff Verlag, GmbH & Co. KG, Darmstadt 1996

Authors and Affiliations

  • P. Bärtsch

There are no affiliations available

Personalised recommendations